Long

Bullish View on Clovis Oncology

Bullish view on Clovis Oncology as it breaks $30 price resistance.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
clovisCLVSTrend Analysis

Also on:

Disclaimer